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ABSTRACT
This study investigated the mechanisms of multidrug resistance (MDR) in an isolate of Bacteroides fragilis
(WI1) from a patient with anaerobic sepsis. The MDR of WI1 affected susceptibility to b-lactams,
clindamycin, ﬂuoroquinolones, metronidazole and tetracycline. In addition to its 5.31-Mb chromosome,
WI1 possessed two low-copy-number plasmids, pHagl (5.6 kb) and pHag2 (9.9 kb), that were absent
from B. fragilis NCTC 9343. Restriction digestion with EcoRV, HindIII and SstI, combined with DNA
sequencing, revealed that pHAG2 contained a tet(Q) gene at base position 3689 that resided on the
conjugative transposon CTn341. Genes cﬁA (encoding a metallo-b-lactamase) and erm(F) (encoding a
macrolide–lincosamide–streptogramin B resistance determinant) were also found in WI1, but were
absent from B. fragilis NCTC 9343. Nitroceﬁn hydrolysis revealed that WI1 had high b-lactamase
activity. Sequencing of the gyrA quinolone resistance-determining region revealed a mutation causing a
Ser82 ﬁ Phe substitution, and comparative quantitative real-time RT-PCR revealed that the cﬁA, erm(F)
and tet(Q) genes were all expressed in WI1. In addition, the resistance–nodulation–division efﬂux pump
genes bmeB9 and bmeB15 were signiﬁcantly over-expressed (12.30 ± 0.42-fold and 3541.1 ± 95.4-fold,
respectively), and the efﬂux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone and reserpine
signiﬁcantly increased the susceptibility of the isolate to several unrelated antibiotics (p <0.005). These
data suggested that WI1 was highly multidrug-resistant because of the additive effects of chromosome-
and plasmid-encoded resistance determinants.
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INTRODUCTION
The Bacteroides fragilis group of organisms in-
cludes the anaerobic bacteria of greatest clinical
importance. Optimal empirical therapy with
appropriate antibiotics has been shown to be
important for a favourable clinical outcome [1–3].
Penicillins, cephalosporins, carbapenems, clinda-
mycin, the newer ﬂuoroquinolones and metroni-
dazole are all used (to different degrees in
different hospitals and countries) to treat infec-
tions caused by anaerobes in general, and B. fra-
gilis in particular. Perhaps, in part, because of the
variability in prescribing patterns, the antibio-
grams of anaerobic bacteria have become increas-
ingly unpredictable during recent years, and there
has been an increase in reports of B. fragilis
isolates with a broad spectrum of resistance to
antimicrobial agents, including resistance devel-
oping during treatment [4,5] (42nd Interscience
Conference on Antimicrobial Agents and Chemo-
therapy, abstract E-69). Antibiotic resistance in
B. fragilis can be mediated by endogenous chro-
mosomal genes, or by exogenous genes incorpor-
ated into the chromosome via transposons, or
harboured on extrachromosomal plasmids with
or without transposons [6,7].
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Widespread resistance to b-lactam antibiotics is
mediated by chromosomal b-lactamases, with
carbapenem resistance mediated by the metallo-
b-lactamase CﬁA [8]; increased expression of the
cﬁA gene may be the result of spontaneous muta-
tion and selection by carbapenems. Tetracycline
resistance in B. fragilis (seen in two-thirds of
isolates) is mediated by ribosomal protection
caused by Tet(Q), and is associated most often
with large conjugative transposons located in the
chromosome [9]. Transfer of tetracycline resistance
is inducible and can also facilitate the transfer of
other antibiotic resistance and cryptic plasmids [9].
Clindamycin resistance determinants, erm(A–F),
are distributed widely in nature [10]. They are
found on both plasmids and chromosomes, and
probably reside on a transferable transposon
[11,12]. The erm(F) determinant is generally
responsible for macrolide–lincosamide–strepto-
gramin B resistance in B. fragilis [13,14], although
both erm(B) and erm(G) have also been found
[9,11,15]. Shoemaker et al. [9] demonstrated that
B. fragilis can also acquire erm genes from other
bacterial species, particularly erm(B) from Clostrid-
ium perfringens and erm(G) from Bacillus sphaericus.
This ismainly a result of the high genetic ﬂuidity of
the B. fragilis genome and the mixed population of
bacteria in the intestine.
Increased efﬂux, along with modiﬁcation of the
genes for topoisomerase II and ⁄ or topoisomerase
IV, confers ﬂuoroquinolone resistance. The most
common modiﬁcation is a Ser82 ﬁ Phe substitu-
tion that occurs in the quinolone resistance-deter-
mining region of GyrA. These mutations cause
ﬂuoroquinolone resistance by inhibiting sub-
strate–target recognition and binding between
ﬂuoroquinolones and the target topoisomerase
protein [16].
Metronidazole is a drug that is used commonly
for treatment of anaerobic infections. Resistance
to metronidazole is rare, although resistance
genes nimA–F have been identiﬁed on transfer-
able plasmids that have been associated with
sporadic cases of metronidazole resistance in
several hospitals worldwide [17–19]. However,
nim genes have also been detected in Bacteroides
spp. for which the MICs are below the therapeutic
breakpoint of 16 mg ⁄L, and which are therefore
considered susceptible, thereby demonstrating
that the presence of a nim gene does not neces-
sarily confer clinically relevant levels of metroni-
dazole resistance. In such cases, the nim gene may
not be expressed, or may be expressed only at
very low levels [20,21].
A few isolates exhibiting multidrug resistance
(MDR) to at least three antimicrobial classes have
been found [4,5,22]. In other bacteria, MDR has
been attributed to the over-expression of broad-
spectrum efﬂux pump genes [23], but it is only
during the past 7 years that the role of efﬂux
pumps has been demonstrated in Bacteroides spp.
[24–26].
In 2005, Wareham et al. [27] described a
B. fragilis isolate, henceforth referred to as strain
WI1, from a patient with anaerobic sepsis. This
isolate was resistant simultaneously to metro-
nidazole, b-lactams (including carbapenems),
b-lactam ⁄b-lactamase inhibitor combinations,
macrolides and tetracyclines. Although microbio-
logical cure was apparently achieved with linezo-
lid (an oxazolidinone antibiotic), the patient
succumbed ultimately to ischaemic bowel disease
and died. The aim of the present study was to
identify and characterise the mechanism(s) of
MDR in this B. fragilis isolate.
MATERIALS AND METHODS
Bacterial strains
B. fragilisWI1 was isolated from a clinical sample by Wareham
et al. [27]. The control strain used in this study was the
B. fragilis type strain NCTC 9343 (ATCC25285). B. fragilis
strains were cultured routinely in Brucella broth, or on
Brucella blood agar plates, and were incubated under anaer-
obic conditions (CO2 5%, H2 10%, N2 85%, v ⁄v) at 37C for
24–48 h. Escherichia coli strains DH5-a and XL-1 Blue were
cultured in Luria–Bertani broth or agar under aerobic condi-
tions at 37C for 12–24 h.
DNA procedures
Total cellular DNA was isolated from bacterial whole-cell
suspensions by boiling at 98C for 10 min. Chromosomal
DNA was isolated with a DNeasy tissue kit (Qiagen, Valencia,
CA, USA), used according to the manufacturer’s instructions.
Plasmid DNA was extracted from strains grown to late log-
arithmic phase in 250 mL of Brucella broth using a HiSpeed
plasmid maxi kit (Qiagen), or on a small scale from 5 mL of
brain–heart infusion cultures, using Qiagen spin columns.
Plasmid elimination was attempted as described previously
[28]. In brief, a 0.01-mL inoculumof a brain–heart infusion broth
culture containing 108 cells ⁄mL was added to brain–heart
infusion broth containing acridine orange 25 mg ⁄L, SDS
0.025% w ⁄v or rifampicin 2.5 mg ⁄L and was then grown
anaerobically at 37C for 48 h, followed by subculture on brain–
heart infusion plates and incubation for 48 h. Fifty colonieswere
then selected from each plate, and plasmid extraction was
attempted as described above.
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Transformation experiments were performed by the heat-
shock method [28], with selection of putative transformants on
agar plates containing tetracycline 2 mg ⁄L.
Plasmid DNA samples were analysed by restriction diges-
tion with EcoRV, HindIII and SstI (New England Biolabs,
Beverly, MA, USA) and horizontal agarose gel electrophoresis.
Genes of interest were ampliﬁed from total cellular DNA by
PCR with primers described previously for the cﬁA [8], erm(F)
[13], nimA–D [19] and tet(Q) [9] genes.
Topoisomerase genes were ampliﬁed with the following
primers: gyrA-forward, 5¢-CTACGGAATGATGGAACTGG;
gyrA-reverse, 5¢-TGTTCAGACGTGCTTCAGTG; parC-for-
ward, 5¢-ATAGGCTCCTTGTTGCTGCC; and parC-reverse,
5¢-CGCATCCTGCACTCCATGAA.
PCR products were sequenced on an ABI 300 Prism DNA
sequencer (Laguna Scientiﬁc, Laguna Niguel, CA, USA). For
limited plasmid DNA sequencing, the plasmid was digested
with SstI and cloned as two separate fragments (Fig. 1, lane 6)
in the positive selection plasmid pGATA (Cambrex, Woking-
ham, UK), introduced by transformation into E. coli XL1-Blue,
and selected on Luria–Bertani plates containing ampicillin
(100 mg ⁄L) and the indicator isopropyl thio-b-D-galactoside.
The plasmids were extracted and the inserts sequenced using
ABI dye termination chemistry, with T3 and T7 primers. Full
plasmid sequencing was performed at the Sanger Centre,
Hinxton, Cambridge, UK (http://www.sanger.ac.uk/Pro-
jects/Plasmids/ sequence to be released).
Transcription analyses
Total cellular RNA was isolated from logarithmic-phase cells
(OD600 0.4) with an RNeasy Protect kit (Qiagen). Gene expres-
sion was quantiﬁed by comparative quantitative real-time RT-
PCR with the Quantitect SYBR Green one-step RT-PCR kit
(Qiagen) on a SmartCycler (Cepheid, Sunnyvale, CA, USA).
Final amounts of 250 ng of RNA were converted to cDNA and
reactions were normalised with 16S rRNA [26]. The following





TCACACCGTCACGGTCA-3¢. Primers used for bmeB efﬂux
pump genes have been described previously [26]. Expression
was quantiﬁed by the DDCt approximation method [26]. Data
were analysed by the Student t-test, with p £0.05 considered to
be signiﬁcant. A two-fold or greater difference in expression
was considered to be signiﬁcant.
Phenotypic assays
MICs of cefoxitin, ciproﬂoxacin, clindamycin, imipenem,
metronidazole, norﬂoxacin and tetracycline were determined
by the spiral gradient endpoint method [29]. In brief, an
antibiotic was deposited in a radially decreasing concentration
gradient from the centre to the outside of the plate using an
Autoplate 4000 Spiral Plater (Advanced Instruments, Nor-
wood, MA, USA) and the plate was inoculated with a culture
equivalent to a 0.5 · MacFarland standard. The plates were
incubated for 24–48 h at 37C under anaerobic conditions.
Bacteria grew from the edge of the plate towards the centre.
The drug concentration at the point at which growth ceased
was considered to be the MIC.
The effects of two efﬂux pump inhibitors (EPIs), carbonyl
cyanide m-chlorophenylhydrazone (CCCP) and reserpine,
were determined by measuring the decrease in MIC after
incorporation of these compounds into the assay plate. EPIs
were added uniformly to Brucella blood agar plates at a ﬁnal
concentration of 25 mg ⁄L. The MICs of both CCCP and
reserpine for strains NCTC 9343 and WI1 were >128 mg ⁄L
(results not shown). The EPI-containing agar plates were
incubated for 15 min at room temperature, after which
antimicrobial agents were added in a radial concentration
gradient and MICs were measured as described above.
Production of b-lactamase was assayed with nitroceﬁn
disks (Fisher Scientiﬁc, Hampton, NH, USA), according to the
manufacturer’s instructions.
RESULTS
Phenotype of WI1 and susceptibility to
antibiotics with or without efﬂux inhibitors
WI1 showed a high level of b-lactamase activity
and was >50-fold more resistant than strain
NCTC 9343 to all agents tested. The addition of
CCCP or reserpine reduced the MICs of cefoxitin,
clindamycin, metronidazole and norﬂoxacin by at
least two-fold in WI1. The effect of reserpine on
the norﬂoxacin MIC was four-fold greater than
that of CCCP. Neither CCCP nor reserpine had an









Fig. 1. Extraction and analysis of plasmid DNA from
isolate WI1. Lanes: 1, k HindIII size markers (in descending
order: 23.1, 9.4, 6.6, 4.4, 2.3 and 2.0 kb); 2, negative; 3, uncut
plasmid DNA; 4, EcoRV-digested plasmid DNA; 5,
HindIII-digested plasmid DNA; 6, SstI-digested plasmid
DNA; 7, negative; 8, 1-kb ladder DNA (in descending
order: 10, 8, 6, 5, 3, 2, 1.5 and 1 kb; New England Biolabs,
Beverly, MA, USA).
Pumbwe et al. Bacteroides fragilis and multidrug resistance 185
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 183–189
Genotype of WI1 and gene expression
Restriction digestion of plasmid DNA with
EcoRV, HindIII and SstI gave distinct restriction
patterns (Fig. 1). Plasmid curing experiments
failed to eliminate the plasmid DNA from WI1,
and attempts to transform E. coli DH5-a-compet-
ent cells yielded no transformants on plates
containing tetracycline 2 mg ⁄L. Sequencing of
the terminii of the two cloned inserts (Fig. 1,
lane 6) revealed that the plasmid fragments
resided on two plasmids, named pHag1 (5.6 kb)
and pHag2 (9.9 kb), and contained DNA se-
quences that are normally part of the chromo-
some of B. fragilis YCH46 and Bacteriodes
thetaiotaomicron, plus a sequence that is common
to both B. fragilis YCH46 and NCTC 9343 on the
conjugative transposon CTn341 [6]. The genes for
Tet(Q) and a putative amino-ribosyl transferase
were also detected on pHag2. The tet(Q) gene was
located at base position 3689 of pHag2, and was
carried on a fragment of DNA that was identical
to CTn341. Also present were two putative two-
component regulators, located at base positions
1040 and 1371, respectively, and a gene encoding
a mobilisation (Mob) protein at base position
9184 (http://www.sanger.ac.uk/Projects/Plas
mids/ sequence to be released). The putative
regulators could regulate tet(Q) expression, and
the mob gene could contribute to the mobilisation
of genes between different genomes. pHag1
comprised mostly genes encoding putative ex-
ported proteins and a Mob protein.
The cﬁA (728 bp), erm(F) (466 bp) and tet(Q)
(758 bp) genes were all detected by PCR in WI1,
but no nim genes were found (Table 2). Expres-
sion analyses for cﬁA (182 bp), erm(F) (185 bp)
and tet(Q) (160 bp) revealed detectable tran-
scripts. Real-time RT-PCR also showed increased
expression of bmeB9 and bmeB15 compared with
B. fragilis NCTC 9343 (12.30 ± 0.42-fold and
3541.1 ± 95.4-fold, respectively). Sequencing of
the gyrA and parC genes revealed that isolate
WI1 had a point mutation (C to T) in gyrA,
resulting in a Ser82 ﬁ Phe substitution in the
GyrA quinolone resistance-determining region,
but no mutations in parC were detected.
DISCUSSION
B. fragilis is known to be intrinsically resistant to
several antibiotics, but there has been an
upward trend in the levels and prevalence of
acquired resistance. Extensive studies have
shown that resistance patterns vary among
hospital settings and geographical regions. The
isolate (WI1) described in this study was >50-
fold more resistant than NCTC 9343 to nearly
all known antibiotics, making it an isolate with
MDR.
Isolate WI1 was resistant to clindamycin. Clin-
damycin resistance is generally attributed to the
erm(F) gene [11], which was found to be present
and expressed in this isolate. WI1 was also
investigated for the presence of the erm(B) and
erm(G) genes, but neither was detected.
Table 1. Antibiotic susceptibilities of isolate WI1 com-
pared with Bacteroides fragilis type strain NCTC 9343 in the
presence and absence of carbonyl cyanide m-chlorophe-















Cefoxitin 4 1 2 >256 128 128
Ciproﬂoxacin 2 0.5 0.5 >256 >256 >256
Clindamycin 2 1 2 >256 128 >256
Imipenem 0.25 0.03 0.03 >32 >32 >32
Metronidazole 0.5 0.03 0.25 >256 64 128
Norﬂoxacin 8 8 2 >256 128 32
Tetracycline 0.25 0.25 0.25 >256 >256 >256
Table 2. PCR detection and RT-
PCR of resistance genes in Bactero-
ides fragilis strains NCTC 9343 and
WI1
Gene Description












cﬁA b-Lactam and carbapenem resistance – + – +
erm(F) Lincosamide and macrolide resistance – + – +
nim 5¢-Nitroimidazole resistance – – – –
tet(Q) Tetracycline or 5¢-nitroimidazole resistance – + – +
bmeB9 RND-type efﬂux pump + + 1.0 12.30 ± 0.42b
bmeB15 RND-type efﬂux pump + + 1.0 3541.1 ± 95.4b
aEfﬂux pump expression values were normalised with respect to the transcript detected in the wild-type strain
(NCTC 9343). Expression values are represented as a fold-difference compared with the wild-type.
bValues shown are means ± the standard deviation.
RND, resistance–nodulation–division.
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Interestingly, the resistance proﬁle of WI1
included metronidazole, but nim genes were not
detected. While B. fragilis has generally remained
quite susceptible to metronidazole, a few cases of
resistance have been reported, but have been
attributed to changes in the nim gene or associ-
ated elements (e.g., insertion sequences) [30,31].
Since the nim genes were not detected in WI1,
over-expression of efﬂux pumps may play a role
in the metronidazole resistance observed. How-
ever, since the use of EPIs did not completely
restore sensitivity to metronidazole, it is likely
that other less-established mechanisms of resist-
ance are also involved.
In addition to the several speciﬁc resistance
mechanisms that were operating simultaneously
in WI1, two bmeB efﬂux genes were signiﬁcantly
over-expressed in this isolate (bmeB9 and bmeB15
by 12-fold and 3541-fold, respectively). The pre-
sent data demonstrate that the over-expressed
efﬂux pumps contribute to the resistance of WI1
to at least cefoxitin, clindamycin, metronidazole
and norﬂoxacin. Resistance to cefoxitin and
imipenem was also caused, in part, by cﬁA.
Resistance to tetracycline was most likely to be
caused by tet(Q). Resistance to norﬂoxacin was,
in part, caused by the Ser82 ﬁ Phe substitution
in GyrA. However, although it was clear that
resistance to ciproﬂoxacin was caused partly by
the substitution in GyrA, the role of efﬂux
pumps in resistance to this antibiotic was not
obvious, since no effect of EPIs was detected
(Table 1). It is possible that ciproﬂoxacin (unlike
norﬂoxacin) is a poor substrate for the over-
expressed efﬂux pumps, or that it is an excellent
substrate, so that the effect of EPIs was negligible
in either case. A similar hypothesis could be
made for imipenem. Isolate WI1 was sensitive to
chloramphenicol. Data from the current study
(results not shown) and from other unpublished
studies have shown that chloramphenicol is not a
substrate for the efﬂux pumps investigated to
date in B. fragilis.
The simultaneous interplay of several resist-
ance mechanisms is not surprising and has been
reported previously in several other bacteria [23],
but not to the degree seen in isolate WI1. If a
strain has one mechanism of resistance, especially
if that mechanism provides some degree of cross-
resistance and allows the bacteria to persist, other,
more speciﬁc, single-class mechanisms may be
acquired more easily in a sort of domino effect. It
is tempting to speculate that an increase in efﬂux
pump activity may provide a non-speciﬁc resist-
ance phenotype that allows other mechanisms to
be acquired.
Bacterial genomes vary in size, ranging from
0.46 to 9.7 Mb, with c-group bacterial genomes
being 1.5–5.5 Mb in size (http://www.sang-
er.ac.uk/Projects). The larger the genome size,
the more genetically and metabolically ﬂexible is
the bacterium [32,33]. The B. fragilis genome is
fairly large (5.31 Mb) and is considered to have
signiﬁcant ﬂuidity [34]. Isolate WI1 had acquired
two extrachromosomal plasmids that encoded
several resistance genes, resulting in a more
organised and stable phenotype, as shown by the
failed attempts to eliminate it or transfer it to
E. coli. The ﬁnding that the plasmids contained
sequences normally found on the chromosomes
of B. fragilis and B. thetaiotaomicron, as well as on
transposons of B. fragilis, lends support to the
hypothesis of Salyers et al. [34] that intestinal
bacteria serve as reservoirs of antimicrobial
resistance factors. The combination of the many
single resistance determinants found in B. fragilis
and other intestinal bacteria, coupled with the
ﬂuidity of the B. fragilis genome [34], suggests
that B. fragilis may be capable of acquiring
extrachromosomal resistance determinants, which
will, in turn, give rise to atypical and worrisome
resistance patterns. WI1 is an example of such an
isolate. Levels of multiple resistance that are
nearly this high have been reported only in
strains of Staphylococcus aureus and Enterococcus
faecalis [35,36], and genome sequencing of both
of these strains has also revealed high genetic
ﬂuidity.
The clinical failure of antibiotics in recent years
has been attributed to chromosomally-mediated
mechanisms and the rapid dispersal of plasmid-
borne resistance genes in bacterial populations.
The isolation of a strain with the resistance
phenotype described in this study is a cause for
concern in clinical practice. If the prevalence of
multiple antibiotic-resistant B. fragilis isolates
similar to WI1 increases, there could be a threat
of the spread of B. fragilis equivalents of methi-
cillin-resistant S. aureus or vancomycin-resistant
Ent. faecalis. An understanding of the mechanisms
that underpin MDR and the possible spread of
such resistance in B. fragilis may lead to a more
informed selection of agents for treatment of
anaerobic infections.
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